Book contents
- Frontmatter
- Contents
- Contributors
- Introduction
- I Critical Concepts
- 1 Introduction to Population Diversity and Genetic Testing
- 2 Genotyping Technologies
- 3 Pharmacokinetics: Absorption, Distribution, Metabolism, Excretion Overview Chapter
- 4 Overview: Adverse Drug Reactions
- 5 PharmGKB, a Centralized Resource for Pharmacogenomic Knowledge and Discovery
- 6 DrugBank
- 7 Ethical Considerations for Pharmacogenomics: Privacy and Confidentiality
- 8 Informed Consent in Pharmacogenomic Research and Treatment
- 9 Legal Trends Driving the Clinical Translation of Pharmacogenomics
- II Therapeutic Areas
- References
4 - Overview: Adverse Drug Reactions
from I - Critical Concepts
Published online by Cambridge University Press: 05 June 2012
Book contents
- Frontmatter
- Contents
- Contributors
- Introduction
- I Critical Concepts
- 1 Introduction to Population Diversity and Genetic Testing
- 2 Genotyping Technologies
- 3 Pharmacokinetics: Absorption, Distribution, Metabolism, Excretion Overview Chapter
- 4 Overview: Adverse Drug Reactions
- 5 PharmGKB, a Centralized Resource for Pharmacogenomic Knowledge and Discovery
- 6 DrugBank
- 7 Ethical Considerations for Pharmacogenomics: Privacy and Confidentiality
- 8 Informed Consent in Pharmacogenomic Research and Treatment
- 9 Legal Trends Driving the Clinical Translation of Pharmacogenomics
- II Therapeutic Areas
- References
Summary
Adverse drug reactions occur during drug development and in clinical practice with approved medicines. They are responsible for the termination of approximately 20 percent of investigational drugs in the pharmaceutical pipeline. Approximately 1 percent of marketed drugs are withdrawn or restricted postmarketing because of safety-related issues. Adverse drug reactions affect millions of people every year, are responsible for a significant fraction of hospitalizations, and are a leading cause of death in developed countries. Thus, patients, the medical community, health care providers, regulatory agencies, and the pharmaceutical industry have a compelling interest to understand these adverse reactions and identify factors that influence them.
In this chapter we define adverse drug reactions and several related and commonly used terms; evaluate their impact on drug development, public health, and individual patient well-being; provide an overview of the contribution of known genetic variants to adverse drug reaction risk; and discuss efforts to identify genetic adverse drug reaction risk factors and incorporate them into development and clinical practice.
- Type
- Chapter
- Information
- Principles of Pharmacogenetics and Pharmacogenomics , pp. 27 - 37Publisher: Cambridge University PressPrint publication year: 2012
References
The Importance of Pharmacovigilance: Safety Monitoring of Medicinal ProductsGenevaWorld Health Organization Uppsala Monitoring Centre 2002
1996 http://www.craconnection.com/resources/ich-gcp-resources/53-international-conference-on-harmonisation-good-clinical-practice-guidelines-craconnectioncom.html
Pathogenesis of adverse drug reactionsTextbook of Adverse Drug ReactionsOxfordOxford University Press 1977
Results of a prospective study of acute liver failure at 17 tertiary care centers in the United StatesAnn Intern Med 2002 137 947Google Scholar
Causality assessment of adverse reactions to drugs. I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuriesJ Clin Epidemiol 1993 46 1323Google Scholar
2006 Report from the Slone SurveyBoston, MASlone Epidemiology Center
Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studiesJAMA 1998 279 1200Google Scholar
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patientsBMJ 2004 329 15Google Scholar
National surveillance of emergency department visits for outpatient adverse drug eventsJAMA 2006 296 1858Google Scholar
Risks in new drug development: approval success rates for investigational drugsClin Pharmacol Ther 2001 69 297Google Scholar
The price of innovation: new estimates of drug development costsJ Health Econ 2003 22 151Google Scholar
The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO databaseFundam Clin Pharmacol 2008 22 127Google Scholar
Pharmacovigilance: methods, recent developments and future perspectivesEur J Clin Pharmacol 2008 64 743Google Scholar
Timing of new black box warnings and withdrawals for prescription medicationsJAMA 2002 287 2215Google Scholar
Adverse drug event surveillance and drug withdrawals in the United States, 1969–2002: the importance of reporting suspected reactionsArch Intern Med 2005 165 1363Google Scholar
2009 http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm
The largest prospective warfarin-treated cohort supports genetic forecastingBlood 2009 113 784Google Scholar
Genome-wide association studies for complex traits: consensus, uncertainty and challengesNat Rev Genet 2008 9 356Google Scholar
Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactionsPharmacogenomics J 2009 9 23Google Scholar
The Population Reference Sample, POPRES: a resource for population, disease, and pharmacological genetics researchAm J Hum Genet 2008 83 347Google Scholar
Linkage disequilibrium analysis of biallelic DNA markers, human quantitative trait loci, and threshold-defined case and control subjectsAm J Hum Genet 2000 67 1208Google Scholar
Validating, augmenting and refining genome-wide association signalsNat Rev Genet 2009 10 318Google Scholar
Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesisPharmacogenomics J 2008 8 186Google Scholar
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillinNat Genet 2009 41 816Google Scholar
A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dosePLoS Genet 2009 5Google Scholar
SLCO1B1 variants and statin-induced myopathy – a genomewide studyN Engl J Med 2008 359 789Google Scholar
A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemiaPharmacogenomics J 2004 4 49Google Scholar
The innovative use of a large-scale industry biomedical consortium to research the genetic basis of drug induced serious adverse eventsDrug Discov Today Technol 2007 4 75Google Scholar
Pharmacogenetics in clinical practice: considerations for testingExpert Rev Mol Diagn 2006 6 193Google Scholar
How to assess musculoskeletal conditions. PrognosticsBest Pract Res Clin Rheumatol 2003 17 403Google Scholar
Pharmacogenetics of ABCG2 and adverse reactions to gefitinibJ Natl Cancer Inst 2006 98 1739Google Scholar
Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitisHepatology 2003 37 924Google Scholar
Co-amoxiclav jaundice: clinical and histological features and HLA class II associationGut 2000 47 717Google Scholar
http://www aasld org/conferences/educationtraining/Documents/Hepatoxicity%20Slides/Wright.pdf 2009
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecanJ Clin Oncol 2004 22 1382Google Scholar
Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patientsClin Cancer Res 2004 10 5151Google Scholar
Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control studyPharmacogenomics J 2008 8 29Google Scholar
Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locusJ Natl Cancer Inst 1999 91 2001Google Scholar
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinolProc Natl Acad Sci U S A 2005 102 4134Google Scholar